Assessment of the safety of nimotuzumab in patients suffering from non-small cell lung cancer with brain metastasis

Authors

  • Nadia Aguilera Calvo Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.
  • Ilsa Sofía del Cristo Domínguez Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.
  • Yaima Muñoz Morejón Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.
  • Lisett Palomino Machado Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.
  • Amparo Macías Abraham Centro de Inmunología Molecular. La Habana.

Keywords:

LUNG NEOPLASMS, NEOPLASM METASTASIS

Abstract

Background: nimotuzumab is a novel humanized monoclonal antibody, with antitumor effect, that recognizes the receptor of epidermal growth factor over-expressed in many malignant tumors of epithelial origin such as esophagus, lung, glioblastoma multiforme and prostate. It is used in combination with onco-specific therapies, such as chemotherapy or radio-sensitizer. Up to date, more than 2000 patients have been treated with this product and this is the first monoclonal antibody for pediatric patients registered in the country.
Objective: to describe the adverse events associated to Nimotuzumab in patients suffering from non-small cell lung cancer with brain metastasis in a clinical trial.
Method: the basic characteristics of the patients, as well as the frequency, intensity and causality relation of the reported events were analyzed. The study population was made up of all the patients included in the clinical trial.
Results: most of the adverse effects were: asthenia, anorexia, headache and vertigos, which have been reported in previous studies.
Conclusions: the Nimotuzumab is a safe drug for the treatment of patients suffering from non-small cell lung cancer and brain metastasis.

Downloads

Download data is not yet available.

Author Biographies

Nadia Aguilera Calvo, Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.

Licenciada en Ciencias Farmacéuticas. Máster en Tendencias de la Biotecnología Contemporánea. Asistente de Investigación Clínica.

Ilsa Sofía del Cristo Domínguez, Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.

Especialista de Primer Grado en Medicina General Integral. Asistente de Investigación Clínica.

Yaima Muñoz Morejón, Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.

Especialista de Primer Grado en Medicina General Integral. Especialista de Primer Grado en Microbiología. Máster en Enfermedades Infecciosas. Máster en Bacteriología-Micología. Asistente de Investigación Clínica.

Lisett Palomino Machado, Centro Nacional Coordinador de Ensayos Clínicos (CENCEC), La Habana.

Licenciada en Ciencias Farmacéuticas. Asistente de Investigación Clínica.

Amparo Macías Abraham, Centro de Inmunología Molecular. La Habana.

Especialista de Segundo Grado en Bioquímica Clínica. Doctor en Ciencias Bioquímicas.

References

Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology [revista en internet]. 1997 [citado 3 de septiembre 2015]; 3(1): 71-81. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/9154469.

Naranjo CA, Shear NH, Busto U. Adverse drug reactions. En: Kalant H, Roschlau WHE, eds. Principles of medical pharmacology. 6 ed. New York: Oxford University Press; 1998. p. 791-800.

Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, et al. Clinical Experience with nimotuzumab in Cuban Pediatric Patients with Brain Tumors, 2005 to 2007. MEDICC Rev. [revista en internet]. 2009 [citado 3 de septiembre 2015] 11(3): 27-33. Disponible en: http://www.ncbi.nlm.nih.gov /pubmed/21483304.

Winquist E, Nabid A, Sicheri D, Ganguly P, Venkatesan V, Schneider K, et al. A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT). Proc Am Soc Clin Oncol [revista en internet]. 2002 [citado 3 de septiembre 2015]; 21. Disponible en: http://www.drupjournal. com/article/S1368-7646%2802%2900106-1/references.

Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody nimotuzumab in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol [revista en internet]. 2004 [citado 3 de septiembre 2015]; 22(9): 1646-54. Disponible en: http://jco.ascopubs.org/content/22/9/16 46.full.

Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther [revista en internet]. 2006 [citado 3 de septiembre 2015]; 5(4): 375-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16575203.

Cimaher (nimotuzumab). Resumen de las características del producto [en línea]. La Habana: CIMAB S.A. 2013 [citada 4 diciembre 2013]. Disponible en: http://www.cecmed.cu/Pages/RCP_Med.htm.

Cabañas R, Saurez G, Ríos M, Alert J, Reyes A, Valdés J, et al. Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience. MABS. [revista en internet]. 2013 [citado 3 de septiembre 2015]; 5(2): 202-7. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23575267.

Piedra P, Morejón O. Report of the Fifth nimotuzumab Global Meeting. Biotecnol Apl [revista en internet]. 2010 [citado 3 de septiembre 2015]; 27(1): 56-61. Disponible en: http://www.cimab-sa.com/ publicaciones/596940226.PDF.

Sánchez B, Aguiar Y, Hernández DR, Garrido G, Pérez R, Fernández LE. Report of the Fifth Nimotuzumab Global Meeting. Biotecnol Apl [revista en internet]. 2010, Mar [citado 3 de septiembre 2015]; 27(1): 342-344. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-285220100001000 07&lng=es.

Downloads

Published

2015-06-15

How to Cite

1.
Aguilera Calvo N, del Cristo Domínguez IS, Muñoz Morejón Y, Palomino Machado L, Macías Abraham A. Assessment of the safety of nimotuzumab in patients suffering from non-small cell lung cancer with brain metastasis. Rev. electron. Zoilo [Internet]. 2015 Jun. 15 [cited 2025 Sep. 9];40(9). Available from: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/311

Issue

Vol. 40 No. 9 (2015): September

Section

Original articles

License

This journal provides free and immediate access to its content under the principle that making research freely available to the public supports a greater exchange of global knowledge. This means that the authors transfer the copyright to the journal, so that copies and distribution of the contents can be made by any means, as long as the authors' acknowledgment is maintained. These terms are a reflection that the journal assumes copyright under Creative Commons licenses, specifically under a Creative Commons Attribution 4.0 International license.

Registration and submission of articles to the journal is free. The processing, including review, editing and publication, is completely free of charge.